Compare GSK plc (GSK) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Roundhill Magnificent Seven ETF — how do they compare? GSK plc trades at $50.36 (market cap $102.60B), while Roundhill Magnificent Seven ETF trades at $67.66. The key difference: GSK plc pays a 3.57% dividend while Roundhill Magnificent Seven ETF pays none, and Roundhill Magnificent Seven ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| GSK | MAGS | |
|---|---|---|
Market Cap | $102.60B | — |
Sector | Health | Sector/Thematic |
52-Week High | $61.18 | $70.94 |
52-Week Low | $38.22 | $55.39 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
MAGS (Roundhill Magnificent Seven ETF) trades at $67.71, down 1.93% amid broader rotation away from concentrated tech exposure. Technical indicators show bullish moving averages but overbought RSI levels, with key support at $67. Recent news highlights the ETF's 181% gain since launch but notes underperformance versus the S&P 500 this year as AI spending pressures tech balance sheets.
The ETF faces headwinds from compressed hyperscaler valuations and declining payout ratios, though AI revenue growth potential remains. Risks include concentration in seven mega-caps and market broadening away from tech leadership. Analyst sentiment is mixed, balancing long-term AI themes against near-term valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
